Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion At the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

NCT04474470 is registered in ClinicalTrials.gov with TyrNovo Ltd. as lead sponsor.

NCT NCT04474470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04474470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion At the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
Lead sponsor
TyrNovo Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
September 3, 2020
Completion date
May 8, 2024
Enrollment
52 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, head and neck cancer, metastatic solid tumor, recurrent solid tumor, solid tumor, adult, squamous cell carcinoma of head and neck